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ABSTRACT 
INTRODUCTION: 
Acute pancreatitis is one among the commonest acute abdominal conditions 
presenting to casualty. Most commonly it is Ethanol related acute pancreatitis. CT 
abdomen has been used widely to diagnose and also to exclude other acute abdominal 
condtions.Serum amylase is still being widely used to assist the diagnosis of acute 
pancreatitis. Most of the cases with typical symptoms can be diagnosed clinically but 
still few cases with atypical/mild symptoms with normal or subclinical serum amylase 
become difficult to diagnose. So this may result in misdiagnosis of cases of acute 
pancreatitis.Many newer investigations like serum procalcitonin, IL,IL -6 and urinary 
trypsinogen-2 are now used in the diagnosis of acute pancreatitis. But most of these 
investigations are expensive and require trained personnel. Reports from Saxon et al1, 
Budd et al2, and Gambill et al3has shown that the hourly excretion rate of urinary 
amylase could be more frequently abnormal in the presence of pancreatic diseases 
than the serum concentration of either amylase or lipase.Thus this study is done to 
find the significance of urinary amylase levels and its comparison with serum amylase 
and serum lipase in cases of acute pancreatitis. 
Materials and Methods: 
All patients admitted in Thanjavur medical college Hospital, during 2016 December to 
2017September with clinically suspected acute pancreatitis in the age group 25-45 and 
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with CT findings suggestive of acute pancreatitis were included in the study. Those 
with comorbidities like diabetes mellitus, hypertension and chronic kidney disease and 
those not willing for the investigations were not included in the study. In these cases 
serum amylase, urinary amylase (both done by Kit method with reagent used CNP-
G3), and serum lipase (enzyme calorimetric method) was done within 24 hours of 
admission.Other investigations like complete hemogram, renal function test, were 
done and BISAP score was used in assessing the severity of pancreatitis. Reports were 
collected within one day and the values were compared. Their clinical significance 
and sensitivity in the diagnosis of acute pancreatitis, and its correlation to severity was 
analysed.Datas were entered and analysed statistically. 
Results:  
A total of fifty in patientswith acute pancreatitis were studied. All in the age group 25-
45 years. Out of the fifty cases 48 were male and 2 female. Among the 50 cases 44 
were due to alcohol related pancreatitis and 6 due to gallstones. Duration of symptoms 
was less than 4 days in 32 patients (64%) and more than4 days in 18 members 
(36%).SIRS was evident in 38patients (76%) and was not present in the rest 12 
patients (24%). BISAP Score was 0-2 in 47 patients(94%) and 3-5 in 3 patients(6%). 
Based on CTSI 38 cases(76%) had mild acute pancreatitis(0-3) and 12(24%) had 
moderate acute pancreatitis(4-6), none had severe acute pancreatitis(7-10).Urinary 
amylase was elevated in all 50 cases(100%).Serum amylase was elevated >100 in 39 
cases(78%),but significant (three times the upper limit >300) in 18 cases(36%), and 
11 cases had normal values (22%). Serum lipase was elevated (>60) in 49 cases(98%) 
and normal in only 1 case (2%).Also urinary amylase was grossly elevated (>1001) in 
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patients with BISAP Score >2 and CTSI >3.The sensitivity of serum amylase for 
value >100 was found to be 70%, and the sensitivity of urinary amylase value >500 
was found to be around 83%. 
Interpretation and conclusion: 
In this study it was found that urine amylase was more consistently elevated in all 
patients with acute pancreatitis, and also in cases where serum amylase was in the 
normal range. Most of the cases with normal or low serum amylase values were those 
who had duration of symptoms less than 3 days. Thus urinary amylase measurement 
can be used as more sensitive tool in diagnosis of acute pancreatitis when compared to 
serum amylase, especially in those with late clinical presentation of acute pancreatitis. 
Urinary amylase was also correlating with severity of pancreatitis being grossly 
elevated in patients with moderate acute pancreatitis than mild acute pancreatitis. 
Keywords: 
Acute pancreatitis, Urinary amylase, CTSI, BISAP score, Serum amylase, Serum 
lipase. 
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CHAPTER 1 : INTRODUCTION 
Acute pancreatitis (AP) remains one of the most important cause of acute abdominal 
pain presenting in casualties, especially in our country where alcohol abuse is more 
common. Gallstone disease is identified as the most common aetiology of the first 
attack, accounting for 30–50%.Alcohol association is between 20 and 40% of patients 
with AP4.Worldwide, the main aetiology is biliary tract disease (41%) and alcohol 
abuse (31.7%). 
The clinical course may range from mild discomfort with minimal pancreatic 
inflammation(80%) to severe necrotizing pancreatitis, complicated by multiorgan 
system failure and death(20%).Thuscareful clinicalassessment and the judicial use of 
biochemical tests and radiological imaging enables us to differentiate AP from other 
causesof acute abdomen and to assess the severity of disease. 
 
Serum amylase is being utilized more frequently than any other test in assisting the 
diagnosis of acute pancreatitis. The diagnosis of pancreatitis is usually not a problem 
in the patients with typical symptoms of acute pancreatitis or elevated serum amylase 
values. Diagnostic problems are encountered in the acute cases with atypical 
presentation or that have partially subsided or in the atypical cases with normal or 
subclinical serum amylase values. 
 
 In such cases, pancreatitis may be overlooked, diagnostic studies may be omitted, and 
hospitalization may not be indicated leading to misdiagnosis and increased morbidity 
and mortality from AP.Thus many newer investigations like serum procalcitonin,IL -6 
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and urinary trypsinogen-2 are now used in the diagnosis of acute pancreatitis. But 
most of these investigations are expensive and require trained personnel. 
 
Reports from Saxon et al1, Budd et al2, and Gambill et al3 has shown that the hourly 
excretion rate of urinary amylase could be more frequently abnormal in the presence 
of pancreatic diseases than the serum concentration of either amylase or lipase. Serum 
amylase usually remains elevated for 3–5 days in uncomplicated AP.Lower activities 
do not rule out the diagnosis as serum amylase activity may reduce or normalise 
within the first 24-48 hours. Measurement of urinary amylase activity, which remains 
high for longer periods, may be helpful in this situation5. 
 
Urinary amylase is increased in acute pancreatitis and may remain elevated for 7 to 10 
days after serum levels have returned to normal6.Thus it is useful in diagnosis of  
atypical cases with normal serum amylase and those cases with late presentation of 
AP.  
 
Urinary amylase may also be useful in cases of hypertriglyceridemia and 
macroamylasemia in which serum amylase values may be misguiding diagnosis of 
AP.Thus this study is done to find the significance of urinary amylase levels and its 
comparison with serum amylase and serum lipase  in cases of acute pancreatitis. 
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CHAPTER 2 : AIMS & OBJECTIVES 
AIMS:   
 To compare the values of serum amylase, serum lipase and urinary amylase, and 
determining their significance in diagnosing acute pancreatitis immediately and after 
few days. 
OBJECTIVES: 
1. To determine and compare the values of serum amylase, serum lipase and urinary 
amylase in patients with acute pancreatitis. 
2. To find the significance of urinary amylase and its sensitivity in diagnosing patients 
with acute pancreatitis. 
3.To assess the correlation of severity of acute pancreatitis using BISAP score and 
CTSI with urinary excretion of amylase. 
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REVIEW OF LITERATURE 
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3.1. ANATOMY OF PANCREAS 
 
EMROYOLOGY: 
 
The precursors of the pancreas appear early in developmentas protrusions from the 
primitive gut at astage when it is simple and quite small (Fig.1). Althoughthe ventral 
and dorsal primordia are on oppositesides of the primitive gut, they are in fact very 
close to each other. In the ventral region, the ventralpancreatic primordium develops 
along with the primordiaof the liver, gallbladder, and associated ducts (Fig.2). While 
the dorsal and ventral pancreaticprimordia are expanding, the part of the primitivegut 
that gives rise to them is also growing and changing.[1] 
 
The part of the primitive gut which forms theduodenum grows more on one side than 
another, androtates to the right. The ventral pancreas comes to lie adjacent and 
immediatelyposterior to the dorsal pancreas, and the ducts from the hepatic system 
and theventral pancreas join the duodenum close to wherethe duct of the dorsal 
pancreas joins the duodenum. The dorsal pancreas and ventral pancreas fuse. Their 
ducts anastomose (Fig.2). 
 
The Wirsung’sduct is formed from the ventral pancreatic duct plusthe distal part of the 
dorsal pancreatic duct. The accessory pancreatic duct is formed from the remainderof 
the dorsal pancreatic duct, emptyinginto the duodenum at the minor papilla. The bile 
ductempties into the duodenum along with the main pancreaticduct at the major 
papilla.[2] 
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Fig.1.         Fig.2. 
 
 
 
CONGENITAL ANOMALIES THE EXTRAHEPATIC BILE DUCTS 
AND PANCREAS: 
 
1. Pancreaticobiliary Maljunction. 
 
PBM is a congenital anomaly in which the junction ofthe pancreatic duct and biliary 
duct is located outsidethe duodenal wall (Fig.3); in the normal Pancreaticobiliary 
junction, the main pancreatic duct (MPD, Wirsung’s duct) joins with the common bile 
duct(CBD) inside the muscle layer of the duodenum toform the ampulla of Vater 
(Fig.4).In the case of PBM, the union of theducts is situated external to the muscle 
layer of theduodenum, forming an extension to the muscularispropria of the 
duodenum, thus forms an extendedcommon channel [3]. 
 
The ductaljunction angle is less sharp in these patients than in controlcases. The well-
developed sphincter muscle is situatedin the sub mucosal layer, as in controls, but it 
mainlysurrounds the common channel (sphincter ampullae);the sphincter choledochus 
is extremely hypoplastic.The anatomical findings suggest a probabilityof 
communication between the ducts in casesof PBM. 
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As the intraductal pressure of the pancreaticduct is normally higher than that of the 
bile duct [4],reflux of pancreatic juice may occur into the bile ductand can cause 
nonsuppurative chronic inflammationof the bile duct.  
 
Fig.3        Fig.4 
 
2. Pancreas Divisum 
 
The parenchyma of the ventralpancreas and the dorsal pancreas are separated asa 
double pancreas in pancreas divisum. Recently, however, the term pancreas 
divisum has been used widely to describe two ductal systems, the ventral pancreatic 
duct and thedorsal pancreatic duct, which do not unite or communicateand separately 
drain to the two duodenalpapillae [5]. 
 
P a g e  | 28 
 
In this condition, pancreatic juice fromthe dominant dorsal moiety flows out only 
throughthe minor papilla, in which the outlet is notably smallin most cases.This leads 
to relative outlet obstruction, high intraductal pressure and triggers pancreatitis.This 
raises the question of whether thisvariation plays a role in the development of 
pancreaticpain or pancreatitis. 
 
The clinical relevance of pancreasdivisum has been argued repeatedly [5].This 
conditionstrongly suggests inadequate drainage from the minorpapilla. (Fig 5). 
 
Fig 5. 
 
 
Gross Anatomy 
Pancreas is a retroperitoneal organ that lies in an oblique position. It slopes upward 
from the C-loop of the duodenum to the splenic hilum(Fig 6.).In an adult, the pancreas 
about15 to 20 cm long. It weighs 75 to 100 g.It situation being, so deeply in the 
abdomenand sealed in the retroperitoneum, explains the poorly localized and 
sometimes ill-defined nature with which pancreatic pathology presents.Pain associated 
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with pancreatitis often is characterized as penetrating through to the back due to its 
retroperitoneal location. 
 
The situation of pathology within the pancreas is usually described in relation to four 
regions: the head, neck, body, and tail. The head of the pancreas is posterior to the 
transverse mesocolon and lies in the C-loop of the duodenum.Both renal veins,the 
right renal artery and the vena cava lies just behind the head of the pancreas. The 
Pancreatic neck lies directly over the portal vein. The superior mesenteric vein joins 
the splenic vein and continues toward the porta hepatis as the portal vein, at the 
inferior border of the pancreatic neck.  
 
Usually the inferiormesenteric vein joins the splenic vein, near its junction with the 
portal vein.The superior mesenteric artery runs just to, left of the superior mesenteric 
vein and lies parallel to it. The head of the pancreas and uncinate process wrap around 
the right side of the portal vein and end posteriorly near the space between the 
superior mesenteric artery and superior mesenteric vein. Venous branches draining the 
head of pancreas and uncinate process enter along the posterior and right lateral sides 
of the portal vein. There are no anterior venous tributaries usually, so a plane can be 
easily developed between the pancreatic neck and the portal and superior mesenteric 
veins during resection of pancreas, unless the tumour invades the vein anteriorly. 
The common bile duct lies in a deep groove on the dorsal aspect of the head of 
pancreas until it passes through the parenchyma of pancreas to join the Wirsung’s duct 
at the ampulla of Vater. The body and pancreatic taillie just anterior to the splenic 
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vessels. The splenic vein runs in a groove on the dorsal aspect of pancreas and is fed 
by multiple fragile venous branches from the parenchyma of pancreas. These fragile 
branches should be carefully ligated while performing a spleen-sparing distal 
pancreatectomy. The splenic artery runs just superior and parallel to the splenic vein 
along the posterior superior edge of the pancreaticbody and tail. The splenic artery 
often is tortuous. The body of the pancreas is covered by peritoneum in its anterior 
surface. Once the gastro colic omentum is divided, the body and tail of the pancreas 
can be seen along the floor of the lesser sac, just posterior to the stomach.[6] 
 
 
 
Fig 6. 
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3.2PHYSIOLOGY OF PANCREAS 
 
 
The exocrine pancreas accounts for about 85% of the pancreatic mass, 10% of the 
gland is accounted by extracellular matrix and 4% by blood vessels and the major 
ducts, whereas only 2% of the gland is comprised of endocrine tissue. The exocrine 
and endocrine pancreas are sometimes thought as functionally separate, but different 
components of the organ are coordinated and allows an elegant regulatory feedback 
system, for hormone secretion andrelease of digestive enzymes. This complex system 
regulates the rate, type of digestion, and the distribution and processing of absorbed 
nutrients. The physical approximation of the exocrine pancreas and islets, the presence 
of specific islet hormone receptors on the plasma membranes of acinar cells, and the 
presence of an islet-acinar portal blood system facilitates coordination. Even though 
patients can live without a pancreas, when digestive enzyme andinsulin replacement 
are administered, the loss of this islet-acinar coordination leads to impairments in 
digestive function. Even though only 20% of the normal pancreas is required to 
preventinsufficiency, many patients undergoing pancreatic resection, the remaining 
pancreas is not normal, and pancreatic exocrine and endocrine insufficiency can 
develop with removal of smaller portions of the gland. 
 
Exocrine Pancreas 
 
The pancreas secretes approximately 500 to 800 mL per day of odourless,colourless, 
isosmotic,alkaline pancreatic juice. Pancreatic juice is a combination of duct cell and 
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acinar cell secretions. The acinar cells secrete amylase, lipase and proteases, enzymes 
responsible for digestion of all three food types: carbohydrate, fat and protein. The 
acinar cells are pyramidal in shape, with apices facing the lumen of the acinus. Near 
the apex of each cell are numerous enzyme-containing zymogen granules that fuse 
with the apical cell membrane (Fig.7). Unlike that of endocrine pancreas, where islet 
cells are specialized in secretion of one hormone type, individual acinar cells secrete 
all enzyme types. However, the ratio of different enzymes released is adjusted 
accordingly to the composition of digested food, through nonparallel regulation of 
secretion. 
 
Fig 7. 
 
 
Pancreatic amylase is released in its active form and helps to complete the digestive 
process already begun by salivary amylase. Amylase is the only enzyme secreted in its 
active form by the pancreas, and it hydrolyzes starch and glycogen to glucose, dextrin, 
maltose and maltotriose. These simple sugars are carried across the brush border of 
the intestinal epithelial cells by active transport. Gastric hydrolysis of protein yields 
peptides that enter the intestine and stimulate intestinal endocrine cells to release 
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cholecystokinin (CCK)-releasing peptide, CCK, and secretin,which then stimulate the 
pancreas to secrete enzymes and bicarbonate into the intestine. 
 
The proteolytic enzymes require activation which are secreted as proenzymes. 
Trypsinogen is converted to trypsin (active form), by another enzyme, enterokinase, 
produced by the duodenal mucosal cells. The other proteolytic enzymes are in turn 
activated by trypsin. Trypsinogen activation is preventedwithin the pancreas by the 
presence of inhibitors which are also secreted by the acinar cells. Failure to express, 
pancreatic secretory trypsin inhibitor (PSTI) or SPINK1(normal Trypsinogen 
inhibitor), is a cause of familial pancreatitis.  
 
Inhibition of the activation of Trypsinogenensures that the enzymes within the 
pancreas remain in an inactive state and are activated only within the duodenum. 
Trypsinogen is expressed in several isoforms, a missense mutation on the cationic 
Trypsinogen, or PRSS1, results in premature activation ofTrypsinogen within the 
pancreas. This results in two-thirds of cases of hereditary pancreatitis. 
Chymotrypsinogen is activated to form chymotrypsin. Carboxypeptidase A and 
B,Elastase and phospholipase are also activated by trypsin. Chymotrypsin, trypsin and 
elastase cleaves bond between amino acidswithin a target peptide chain, and 
Carboxypeptidase A and B cleaves amino acids at the terminal end of peptide chains. 
Individual amino acids and smalldipeptides are then transported into the intestinal 
epithelial cells actively. 
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Pancreatic lipase hydrolyzes triglycerides to fattyacid and 2-monoglyceride.Lipase is 
secreted in an active form. Colipase secreted by pancreas, binds to lipase, changing its 
molecularconfiguration and increasing its activity. Phospholipase A2 is secreted as a 
proenzyme and is activated by trypsin.This hydrolyzes phospholipids and requires bile 
salts for its action as all lipases. Cholesterol esterase and carboxylic ester hydrolase 
hydrolyzes neutral lipid substrates like triglycerides, esters of cholesterol and fat-
soluble vitamins. The hydrolysed fat is then packed intomicelles for transport into the 
intestinal epithelial cells, where fatty acids are reassembled and packed inside 
chylomicrons for transportingthrough the lymphatic system into the bloodstream[7] 
(Table 1). 
Table-1 Pancreatic Enzymes 
Enzyme  Substrate Product 
Carbohydrate 
 
Amylase (active) 
Starch, glycogen Glucose, maltose, 
maltotriose dextrins 
Endopeptidases  Cleave bonds between 
amino acids  
Amino acids, dipeptides 
Trypsinogen (inactive)   
Trypsin (active) 
  
Chymotrypsinogen (inactive)  
Chymotrypsin 
(active) 
  
Proelastase (inactive) 
Elastase (active) 
  
Exopeptidases  
 
Procarboxy peptidase A&B 
Cleave amino acids 
from terminal end of 
peptide chains 
— 
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(inactive) 
Carboxypeptidase 
A&B (active) 
 
Fat 
 
Pancreatic lipase (active) 
 
 
Triglycerides 
 
2-Monoglycerides fatty 
acids 
 
Phospholipase A2 (inactive) 
Phospholipase A2 (active)  
 
Phospholipase  
 
— 
Cholesterol esterase Neutral lipids — 
 
 
Endocrine Pancreas 
 
There are nearly 1 million islets of Langerhans in a normal adult pancreas. They vary 
greatly in size from 40 to 900 m. Smaller islets are embedded more deeply in the 
parenchyma of the pancreas and larger islets are located closer to major arterioles. 
Most islets contain 3000 to 4000cells of five major types- alpha cells that secrete 
glucagon, Beta cells that secrete insulin, Delta cells that secrete somatostatin, Epsilon 
cells thatsecrete ghrelin, and PP cells that secrete PP [8](Table 2). 
 
Table 2 Pancreatic Islet Peptide Products 
 
Hormones  Islet Cell  Functions 
Insulin (beta cell) Decreases 
gluconeogenesis, fatty acid 
breakdown,glycogenolysis, 
and ketogenesis 
Increased glycogenesis, 
protein synthesis 
Glucagon (alpha cell) Opposite actions of 
insulin; increased hepatic 
glycogenolysis and 
gluconeogenesis 
Somatostatin (delta cell) Inhibits GI secretion 
Inhibits action and 
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secretion of all GI 
endocrine peptides 
Inhibits cell growth 
 
Pancreatic polypeptide PP (PP cell) Inhibits secretion of insulin 
and pancreatic exocrine 
secretion.  
Facilitates hepatic effect of 
insulin 
Amylin (IAPP)  (beta cell) Counter regulates insulin 
secretion and function 
Pancreastatin (beta cell) Decreases insulin and 
somatostatin release 
Increases glucagon release 
Decreases pancreatic 
exocrine secretion 
Ghrelin (epsilon cell)  Decreases insulin release 
and insulin action 
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3.3. INTRODUCTION TO AP 
 
Acute pancreatitis is a potentially fatal disease.Acute pancreatitis is an acute 
inflammatory processwith variable involvement of the pancreas, regional 
tissuesaround the pancreas, or remote organ systems. The clinical courseranges from 
mild discomfort with minimal inflammation tosevere necrotizing pancreatitis, 
complicated by multiorgan failureand death. The most common etiologies are 
alcoholabuseand gallstones. The natural history is dependent on the degree of necrosis 
and inflammation. An acute attack is usually followedby completerecovery of 
function if the offending agent is identified and removed. 
 
The pathogenesis of acute pancreatitis involves discrete intracellular events that cause 
premature activation of intra-acinar zymogen granules and generate therelease of 
proinflammatory and proapoptotic mediators. Understanding the natural history and 
specific roles of these cytokines may help develop therapies that can alter the course 
of severe pancreatitis and decrease its complications[9]. 
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3.4. AETIOLOGY AND CLASSIFICATION 
 
Acute Pancreatitis may be classified based on aetiology,pathology, severity of disease, 
or the presence of necrosis. Risk factors are summarized in Fig.8. In approximately 
10–20% of patients, no aetiology is identified. Some of them may have microlithiasis 
and/or sphincter of Oddi dysfunction (SOD) as the aetiology of AP. With the 
increasing knowledge and understanding of the role of genetic abnormalities in 
hereditary and idiopathic chronic pancreatitis (CP), it is possible that these 
abnormalities will be implicated in idiopathic AP. Polymorphisms in inflammatory 
mediators may also influence disease severity. 
 
 
Fig 8. 
 
Clinically, AP may be classified as mild or severe disease[10]. SAP is associated with 
organ failure and/or local complications, such as abscess,necrosis or pseudocyst. 
Approximately 10–20% of patients develop severe disease. Various clinical criteria 
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(e.g. Ranson’s or Acute Physiology and Chronic Health Evaluation [APACHE]), 
serum markers (e.g., interleukin [IL]-6, C-reactive protein, and trypsinogen activation 
peptide) and imaging modalities (CECT) have been used to predict severity. 
Complicated courses are more common in SAP with mortalityrates from 5 to 20%[11] 
. In contrast, mild Acute Pancreatitis is the more frequent presentation and has 
minimal or transient organ dysfunction and uneventful recovery. 
 
The presence of necrosis is the single best predictor of outcomeduring AP. Pancreatic 
necrosis is a focal or diffuse area of nonviableparenchyma, typically associated with 
peripancreatic fatnecrosis, which on a contrast CT scan is observed as non-enhanced 
pancreatic parenchyma. The morbidity andmortality can be predicted by the degree of 
necrosis. Approximately 30% of patients with pancreatic necrosisdevelop infected 
necrosis with a mortality of 6 to 40% and a morbidityof more than 80%. 
 
The Revised Atlanta Classification 
 
 The revisions of OAC(Original Atlanta classification) and definitions have been 
updated recently as the Revised Atlanta classification (RAC) [12] according to which 
the diagnosis of AP requires two of the following three features: (1) abdominal pain 
consistent with AP; (2) characteristic findings of acute pancreatitis on contrast-
enhanced computed tomography (CECT) and less commonly magnetic resonance 
imaging or trans abdominal ultrasonography; and (3) serum lipase activity (or amylase 
activity) at least three times greater than the upper limit of normal.[12]. 
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This classification redefines severity of AP into 3 categories mild, moderate and 
severe, and also morphologically describes fluid collections occurring following AP 
[12] In addition, based on the CECT criteria, 2 distinct types of AP: Acute necrotizing 
pancreatitis (ANP) and acute interstitial oedematous pancreatitis have been described. 
ANP is further subdivided into pancreatic parenchymal necrosis aloneperipancreatic 
necrosis alone and pancreatic parenchymal and peripancreatic necrosis [12, 13].  
The classification of severity is primarily based on presence of organ failure (OF) 
which is assessed by modified Marshall scoring system, and local or systemic 
complications (exacerbation of co-morbid conditions) (Fig 9.). SAP is characterized 
by persistent Organ Failure which is indicated by presence and persistence of systemic 
inflammatory response syndrome (SIRS). Persistent Organ failure may involve single 
or multiple organs and such cases usually have one or more local complications. 
These patients are at an increased risk of death, with a mortality reported as high as 
36–50% [12,14]; which may increase further with the development of infected 
necrosis [15, 16]. 
 
In Revised Atlanta Classification the description of fluid collections and their 
terminology has been made precise and it provides the standardization which had been 
a source of controversy in the past few years (Fig 10) 
P a g e  | 41 
 
 
Fig 9. Revised Atlanta classification. 
 
 
Fig 10.Types of fluid collections (Revised Atlanta Classification) 
 
SPECIFIC ETIOLOGIES 
 
GALLSTONES 
Gallstones are implicated in majority of Acute Pancreatitis cases. Although it is 
common, they rarely cause pancreatitis. It is estimated that over a 20- to 30-year 
period, the risk for developing biliary pancreatitis is approximately 2%in patients with 
asymptomatic gallstones. Smaller gallstones, particularly those that are smaller than 5 
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mm in size, increase the risk of Acute Pancreatitis. Patients with microlithiasis can 
present with recurrent episodes of “idiopathic” AP. 
ALCOHOL 
Alcoholic pancreatitis presents as AP, although in most patients, it occurs in the 
presence of already established chronic pancreatitis (CP).It is the most common cause 
of recurrent pancreatitis. The incidence of alcoholic pancreatitis is low (about 5%) in 
alcohol abusers. This suggests that in addition to alcohol ingestion, other factors, such 
as environmental influences or genetic background, may affect patient susceptibility. 
Abnormal SOD spasm, direct toxic effect of alcohol and its metabolites and 
obstruction of the small ducts by proteinaceous material are some physiological 
mechanisms which contribute to the development of alcoholic pancreatitis. 
HYPERLIPIDEMIA 
Hyperlipidaemia is a cause of AP and CP. Triglyceride levels more than 1000 mg/dL 
is usually required for the development of AP. 
DRUGS 
Drugs are a rare cause of AP. Various medications have been implicated in AP. 6-
mercaptopurine,Azathioprine, and 2’, 3’- dideoxyinosine have an unquestionable 
association. Weaker association is seen with drugs like angiotensin-converting 
enzyme inhibitors, and tetracycline. 
ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY 
Acute Pancreatitis is the most common complication of ERCP. Prospective studies 
have documented an incidence of approximately 5% with most cases being mild 
pancreatitis. 
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3.5. PATHOGENESIS OF AP 
The syndrome of AP represents a series of pathological events. The initial pathology 
is likely to involve either the acinar cell or reduced blood flow. Once initiated, the 
process can involve the whole pancreas, its surrounding tissues, and can cause a 
systemic reaction harming many organs. Much of our information is derived from 
experimental animal studiesas human pathological material is rarely available from 
early cases of AP. 
 
ACINAR CELL EVENTS 
Pancreatic acinar cells form approximately 95% of the exocrine mass. In response to 
an initiating insult, the acinar cell mounts three key pathological responses: 
intracellular zymogen activation, inhibited secretion, and the generation and release of 
proinflammatory and proapoptotic mediators (Fig.11). 
 
 
Fig 11.Early and late cellular events in the pathogenesis of acute pancreatitis. 
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ZYMOGEN ACTIVATION AND INHIBITION OF SECRETION 
 
Most of the pancreatic digestive enzymes, including all proteases,are synthesized and 
stored as inactive proenzymes (zymogens).Within the first minute to hours of an 
episode of AP; zymogens are activated within the pancreatic acinar cell [17]. 
Zymogens that have leaked into the interstitium may also be activated at later stages. 
The mechanisms responsible for the acinar cell activation have not yet been fully 
defined. Howeverseveral factors have been consistently identified by experimental 
models. Many of the physiological responses of the acinar cell to neurohumoral 
stimuliis mediated by elevations in cytosolic calcium. 
 
 
When acinar cells are stimulated pathologically, their zymogen and lysosomal 
contents colocalize, whereuponcathepsin B converts trypsinogen to trypsin. Increased 
cytosolic calcium is required for colocalization. Trypsin mediates the permeability of 
these colocalized organelles. Cathepsin B and other contents of these colocalized 
organelles are released into the cytosolonce trypsin has permeabilized the cells. 
Cathepsin B also activates apoptosis by causing cytochrome c to be released from the 
mitochondria. Cathepsin B–induced activation of the Bcl-2 family of proteins helps 
the release of cytochrome c from the mitochondria. Heat shock protein 70 (HSP70) 
overexpression attenuates cytosolic calcium (Ca 2+), thus preventing colocalization 
and thesubsequent events that lead to acinar cell injury and death.(Fig 12) 
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Fig 12. Schematic representation of the pancreatitis hypothesis. 
 
The enterokinase (brush border enzyme), first converts trypsinogen to trypsin and 
then, the other zymogens are activated by trypsin. Since the pancreas does not contain 
enterokinase, some other mechanism must be responsible for activation. 
The leading candidates are activation of trypsinogen by the lysosomal enzyme, 
cathepsin B, or trypsinogen auto activation[18]. Several mechanisms permit cathepsin 
B to mix with trypsinogen. First, even though in the Golgi complex,the lysosomal 
enzymes are usually separated from digestive zymogens, the pancreas directs some of 
the lysosomal enzymes to the secretory compartment. Second, organelles containing 
the two enzyme familiesmay fuse[19].  
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Activation of enzyme alone may not be sufficient to cause acinar cell damage. The 
decreased secretion of proteins from theacinar cellmay have a critical role in disease 
which is observed at the onset of pancreatitis. The disruption of theapical actin 
cytoskeleton may result inreduced secretion. Some conditions that cause zymogen 
activation butleave the secretion intact do not cause acinar cell injury.Thus, both 
retention of enzymes and enzyme activation in the acinarcell may be required to 
initiate disease. 
 
The release oftrypsin into the interstitium has a unique role in causing the severepain 
associated with Acute Pancreatitis. Trypsin may specifically stimulate 
proteaseactivatedreceptors on nerves that carry pain sensation. Sincezymogen 
activation appears to be a very early feature of the disease, theuse of protease 
inhibitors therapeutically may be limited to prophylaxis(e.g., for ERCP-induced AP). 
The importance of zymogenactivation in the pathogenesis of AP is underscored by 
theobservation thatmutations in cationic trypsinogen can cause some forms of 
hereditary pancreatitis and thereby itmight enhance its activation orprolong its 
activity[20]. 
 
CYTOKINE AND CHEMOKINE GENERATION 
Inflammation and cell death are two key features of AP. Neutrophilrecruitment and 
activation are early features of disease and they correlate withthe disease severity. 
Soluble factors, such as tumour necrosis factor(TNF)-alpha and platelet-activating 
factor, are generated by the acinar cellsand stimulate inflammation. Expression of 
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intracellular adhesionmolecule-1 and selectins in the endotheliumpromotes 
inflammatory cell adhesion.Substance P(neurokine) may also have a key role in 
disease. Mononuclear cells may contribute to injury,even in acute disease. 
Cytokinesgenerated by the acinar cell (e.g., TNF-alpha) can also induce 
programmedcell death (apoptosis). Release of these soluble factors from the 
pancreasmay also beresponsible for the lung injury associated with severe 
pancreatitis[21,22]. Multiple cytokines that cause distinct patterns of organ injury are 
released, which makes it unlikely that inhibition of asingle pathway will be an 
effective disease treatment. 
 
PANCREATIC AND PERIPANCREATIC EVENTS 
 
EDEMA 
Increased tissueoncotic pressure and increasedcapillary permeability potentially lead 
to early pancreatic oedema. Such changescontribute to the decreased pancreatic blood 
flowbydiminishing intravascular volume and the compression of vascularstructures. 
 
VASCULAR CHANGES AND FREE RADICAL GENERATION 
Endothelial injury, vasospasm, and vascular thrombosis can all occurin AP. Two 
deleterious outcomes can occur with changes in pancreatic perfusion. Vasospasm with 
later increase in circulation can cause perfusion–reperfusion injury and free radical 
generation. Loss ofperfusion and ischemia can lead directly to cell death. Even though 
there is a strong theoretical and experimental basis for the implementation of free 
radicals in AP, thereis little clinical support for the use of antioxidant therapy. 
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CHANGES IN PARACELLULAR CELL PERMEABILITY 
Loss of the cell structures which form tight seals, known as “tight junctions” occur in 
the acinar and duct cells. This early event occurring within first 30minutes is 
associated with breakdown of the actin cytoskeleton which is ananchor for the tight 
junctions. These disruptions allow the pancreaticduct contents to leak into the 
interstitial space. These changes contributeto the very rapid increase in serum levels of 
pancreaticenzymes and rapid decrease in secretions of pancreas observed at theonset 
of disease. Also, zymogens that enter the interstitial spacemay undergo activation. 
CELL DEATH 
Two mechanisms of cell death are observed in AP: necrosisand apoptosis. The factors 
mediating thetwo mechanisms of death are not clearly understood. Moresevere forms 
of pancreatitis may be however more strongly associated withnecrotic death than 
apoptotic cell death. Necrosis is the earliestand is most prominent in adipose tissue in 
humans. Injured adipocytes may be arich source of harmful cytokines (TNF-alpha) 
and provide substrates(triglycerides) for the generation of harmful free fatty acids. A 
unique form of necrosis after injury; instead of dying, is undergone by the acinar cell, 
the cell may respond to injury by pinching off their apical zymogengranule-rich 
region. This leaves the acini filled with flattened cells—theseglandular structures are 
known as tubular complexes. This response provides a scaffold for rapid regeneration. 
Similarly, high levelsof the pancreatitis-associated protein and the pancreatic 
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stoneprotein generated during the initial days of Acute Pancreatitis may have arole in 
reconstitution. Generally, exocrine and endocrine structure andfunction fully recovers 
from an episode of AP. With severe disease,however some deficiency in function may 
be detected upto 1 year. 
 
SYSTEMIC EVENTS 
Two major processes lead to death in AP, early deaths are caused bymultiorgan failure 
and later deaths by OF and/or infectednecrosis. The SIRS is alsoassociated with 
severe pancreatitis. The lungs are particularly more sensitive tothis injury, and the 
development of ARDSoften indicates severe disease. SIRS and OF can be 
presentupon admission but are often reversible. Even though the presence of someOF 
or SIRS upon admission has a worse prognosis, those patients with deteriorating organ 
functionor persistent SIRS have been observed to have the highest mortality. 
Therelease of these inflammatory cytokines, chemokines, and neurokines lead to 
systemic effects. 
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3.6. CLINICAL FEATURES 
 
Patients with AP usually present with suddenonset of upper abdominal pain, nausea, 
and vomiting. Approximately 80% ofpatients have interstitial pancreatitis with mild-
to-moderate symptoms,and 20% have life-threatening necrotizing disease. Careful 
clinicalassessment, the judicial use of biochemical tests and radiologicalimaging helps 
the practitioner to differentiate AP from other causesof acute abdomen and to assess 
the severity of disease[23-29]. 
 
History and Physical Exam 
 
 
AP is characterized by abdominal pain located in the epigastric region, often radiating 
to the mid-thoracicportion of the back. Pain reaches maximum intensityusually within 
20minutes but can have a more gradual onset. The pain in AP is usuallysharp, 
constant, lasts for hours to days, severe enough to forcethe patient to visit the 
emergency room. 
In mild cases of AP, there may be decrease in pain when sitting or leaning forward in 
comparison to lying flat. 
 
Nausea and vomiting with or without low-grade fever are the mostcommonly 
associated symptoms [23,26,27]. 
Inpatients with alcohol-induced pancreatitis,a recent history of binge drinking may be 
frequently elicited. The concomitant presenceof jaundice and high-grade fever 
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strongly suggests choledocholithiasisas the aetiology of AP, complicated by 
coexistent cholangitis[23-29].  
Lesscommonly, confusion, respiratory failure and even coma are the mainpresenting 
features, which are common manifestations of severenecrotizing pancreatitis. In rare 
cases, abdominal pain may be absent,leading to a delayed or missed diagnosis[23]. 
 
Abdominal distension,tenderness, guarding, and absent bowel sounds are the usual 
findings on a physical examination. Low grade fever is generally associatedwith AP. 
High-grade temperature may indicatethe development of infected pancreatic necrosis 
and associated fluidcollection or cholangitis, particularly if jaundice is present 
[23,24,27,28]. 
SAP is often complicated by massive lossof fluid into retroperitoneal spaces. 
Hypotension and tachycardiaare some of the earliest clues for a moderate-to-severe 
attack of pancreatitisand are also markers for significant early depletion of 
intravascular volume. These may soon progress to hypovolemic shock caused 
byincreased vascular permeability, vasodilatation, and haemorrhage [23]. 
 
Dyspnoea and tachnypnea are also common in severe pancreatitis, dueto 
associatedpleural effusions,splinting from the sub diaphragmatic inflammatory 
process or pulmonary capillary leak syndrome. Pleural effusion is usually found on 
theleft side but can be bilateral. 
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Rare clinical findings include ecchymosis of the umbilicus(Cullen’s sign) or 
flanks(grey turner sign),peripheral subcutaneous fat necrosis, and polyarthritis. 
Classically, darkskin discoloration of the per umbilical areas and flanks occurring 
because of haemorrhageis described with severe and haemorrhagic pancreatitis; 
howeverthese physical findings may result from any type of 
retroperitonealbleeding[28]. 
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3.7. DIFFERENTIAL DIAGNOSIS 
 
 
 
 
Differential diagnosis of Acute pancreatitis [30] 
 
Mild attack 
x Biliary colic or acute cholecystitis 
x Complicated peptic ulcer disease 
x Acute liver conditions 
x Incomplete bowel obstruction 
x Renal disease 
x Lung disease (example, pneumonia or pleurisy) 
 
Severe attack 
x Perforated or ischaemic bowel 
x Ruptured aortic aneurysm 
x Myocardial infarction 
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 3.8. RISK STRATIFICATION IN PANCREATITIS 
 
Early evaluation of severity of AP is essential to allow the clinician topredict the 
patient’s clinical course, determinethe need for intensive care unit admission and 
estimate prognosis. SAP can be predictedby clinical criteria, serum markers,multiple 
factor scoring systems andradiographic features. Most of these scoring systems have 
been developedto assist the clinician in assessing the severity of AP. Themost 
commonly used systems are the Ranson criteria (Fig 13,14.), modifiedGlasgow 
scoring system(Fig 15), and the Acute Physiology And ChronicHealth Evaluation II 
(APACHE II)[31-33]. The Modified Glasgow System and Ranson Criteria rely on 
acollection of clinical and biochemical variables measured within thefirst 48 hours of 
admission. 
 
They are however very cumbersome and complex for quick evaluation. In 2008, the 
Bedside Index for Severity in Acute Pancreatitis (BISAP) score(Fig 16.) was proposed 
for the early recognition of patients at risk of mortality.  
This scoring system is comprised of five variables: Impaired mental status, 
development of systemic inflammatory response syndrome, age > 60 years,blood urea 
nitrogenlevel > 25 mg/dl and presence of pleural effusion [34,35]. BISAP is more 
convenient to use with fewer items when compared with traditional scoring systems. 
  
More novel serum tests have also been evaluated. C-reactive protein(an acute-phase 
reactant) is widely available,cheap and commonly usedin Europe to measure the 
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severity of AP. A level of 150 mg/L of C-reactiveprotein has been proposed as a 
criterion for distinguishing mild APfrom SAP[36]. Other markers like trypsinogen 
activation peptide,polymorph nuclear elastase and interleukin-6 have been shown in 
Research studies to be of value in predicting severe necrotizing pancreatitis,but 
commercial assays are not yet available for clinical use. 
 
 
Fig 13.     Fig 14. 
 
 
       
 Fig15. 
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Fig 16. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BISAP SCORE 
 BUN >25 mg/dL (8.9 mmol/L) (1 point) 
 Abnormal mental status with a 
GCS<15 (1 point) 
 Evidence of SIRS (1 point) 
 Patient age >60 years old (1 point) 
 Imaging study reveals pleural effusion 
(1 point) 
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3.9. INVESTIGATIONS OF AP 
Laboratory Tests 
 
 
The diagnosis of AP is usually suspected based on the appropriateclinical features and 
is confirmed by laboratory and imaging tests.Leakage of pancreatic enzymes into 
thecirculation is a hallmark of AP.Although lipase and amylase constitute a small 
fraction of all pancreaticenzymes, they are the quickest and the easiest enzymes to 
measure.Typically, the elevation of serum amylase in Acute Pancreatitis is more than 
threefold of thenormal values. 
 
Amylase levels are usually increased within a few hours ofdisease onset, but they may 
be cleared from the serum rather quickly.Serum amylase usually remains elevated for 
3–5 days in uncomplicatedAP. Because many conditions can cause hyperamylasemia 
(Table 3),the specificity of elevated serum amylase level is less than 70%.  
Table 3.-Causes of Increased Serum Amylase Activity 
 
 Pancreatic diseases 
Acute pancreatitis 
Pancreatic cancer 
 
 Abdominal emergencies 
Acute cholecystitis 
Common bile duct obstruction 
Perforated viscous 
Intestinal ischemia 
Acute appendicitis 
Ruptured ectopic pregnancy and acute salpingitis 
 
 Salivary gland diseases 
 Renal insufficiency 
 Macroamylasemia 
 Diabetic ketoacidosis 
 HIV infection/AIDS 
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Measurements of urinary amylase and theamylase-to-creatinine ratio may be helpful 
to distinguish AP from othercauses of hyperamylasemia, but such measurements are 
infrequentlyemployed [37]. 
 
In many cases, during pancreatitis urinary clearance of pancreatic enzymes from the 
circulation increases; hence, urinary levels may be more sensitive than serum levels. 
For the above reasons, it is recommended that amylase concentrations to be measured 
in the urine. Urinary amylase levels usually remain increased for manydays after 
serum levels have returned to normal. In patients with severe pancreatitis associated 
with significant necrotic damage, the pancreas may not release large amounts of 
enzymes into the circulation [38]. 
 
Measurements of serum amylase isoenzyme may improve the diagnosticaccuracy of 
serum amylase alone. Less than half ofall circulating amylase originates in the 
pancreas, whereas the remainderis of salivary origin in healthy people. Serum 
pancreatic isoamylase (P-isoamylase)accounts for the elevated total serum amylase 
level in Acute Pancreatitis and it tends topersist for several days. However, pancreatic 
isoamylase can be elevated in renal insufficiency and in some other gastrointestinal 
disorders, makingit difficult to diagnose Acute Pancreatitis based on P-isoamylase 
levels alone withoutadditional diagnostic parameters [39]. 
 
 Sphincter Oddi stenosis or spasm 
 Drugs: Morphine 
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The elevation of serum amylase usually parallels the serum lipase level in Acute 
Pancreatitis. However, the serum lipase level often remains elevatedlonger, making it 
more useful to diagnose pancreatitis after symptoms have subsided. Lipase is 
considered more specific than amylase for pancreatic tissue injury, despite the fact 
that it is also produced by manyother gastrointestinal tissues. Another potential 
advantage of lipase is that it is generally not elevated in diabetic ketoacidosis or 
macroamylasemia[23]. 
 
Both lipase and amylase are widely and rapidly available from hospital laboratories. 
In practice, combining the measurement of serum lipase and amylase levels enhances 
the diagnostic accuracy for Acute Pancreatitis. A normal lipase or amylase level 
makes the diagnosis of Acute Pancreatitis unlikely, except in the presence of 
hyperlipidaemia. 
 
Very high levels of serum triglyceride (one among the causes of Acute Pancreatitis) 
can interfere with the laboratory assay for both lipase and amylase. In such scenarios 
dilution of the serum may be necessary to reliably measure the elevations of lipase 
oramylase. In some patients with chronic pancreatitis, acute abdominal pain can be the 
result of focal acute inflammationof the gland, and serum amylase and lipase levels 
may remain normal[27,28]. 
It is to be noted that a correlation has not been found betweendegree of serum lipase 
and amylase elevation with the severity of Acute Pancreatitisor amount of structural 
damage of the pancreas [36]. 
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Pancreatic enzymes, such as serum trypsin, chymotrypsin, ribonuclease , 
phospholipase A2, and elastase have been reported to be elevated in AP, but to 
measure these enzymes, assays are not readily available for clinical use, and their 
specificity has not been defined [24,27,36].The use of other available clinical 
laboratory tests may help in determining the aetiology of Acute Pancreatitis. For 
example, elevated bilirubin and hepatic transaminases, particularly alanine 
aminotransferase more than 80 IU/L should raise the suspicion of gallstone 
pancreatitis [23-27]. 
 
IMAGING 
 
ULTRASONOGRAPHY 
 
 
Transabdominal ultrasonography is relatively inexpensive,widely available and quite 
safe. Unfortunately, pancreatic imaging by ultrasound has limitations from overlying 
bowel gas and surrounding fat planes, which tend to be exaggerated in the acutely 
inflamed pancreas owing to ileus and peripancreatic edema. Thus the sensitivity and 
specificity of this modality for diagnosing AP is low[23]. Nonetheless, 
transabdominal ultrasonography is useful in the early stages of Acute Pancreatitis to 
search for gallbladder sludge orstones, to evaluate the cause for dilation of the 
common bile duct caused by choledocholithiasis, and analyse for other causes of 
severe abdominal pain. 
 
COMPUTED TOMOGRAPHY SCAN 
 
 
P a g e  | 61 
 
The computed tomography scan(CT), particularly when done withmultidetector 
orhelicaltechnology, is a valuable tool in the management and diagnosis of Acute 
Pancreatitis. However, every patient with AP does not require aCT scan. CT is mainly 
indicated if the initial diagnosis is in doubt orfor prognostic purposes in severely ill 
patients. The role of CT is both to exclude other intra-abdominalpathologies that can 
mimic AP (e.g., a perforated viscus) and to document the findings that confirm the 
diagnosis of AP. 
 
CT scan findings supporting the diagnosis of Acute Pancreatitis include irregularity of 
the pancreatic contour with obliteration of the peripancreatic fat planes, segmental or 
diffuse enlargement of the pancreas, areas of hypo density within the pancreas, and ill-
defined fluid collectionsin the pancreas or outside the gland in the Para renal spaces 
orlesser sac. 
 
The frequency of these findings varies according to the severity of pancreatitis,and 
these findings do not require intravenous contrast CT to be identified.Intravenous 
contrast-enhanced computed tomography (CECT) ismainly used to differentiate 
interstitial pancreatitis from pancreatic necrosis or to monitor the complications in 
selected cases (i.e.,ratherthan simply confirming a diagnosis, helps in estimating 
prognosis and management of  patients with Acute Pancreatitis).(Fig 17.) 
At present, it is recommendedthat CECT be obtained 3–4 days after the onset of SAP 
for optimalassessment of pancreatic necrosis[32]. 
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Fig 17.A CT scan demonstrating a large area of necrosis as evidenced 
by the lack of contrast enhancement after intravenous contrast administration 
 
 
 
CT SEVERITY INDEX 
The CTSI is based on findings from a CT scan with iv contrast to assess the severity 
of acute pancreatitis. The severity of CT findings correlates well with clinical indices 
of severity.  
The CT SEVERITY INDEX sums two scores: 
 Balthazar score: grading of pancreatitis (A-E)  
 grading the extent of pancreatic necrosis 
CTSI 
Grading of pancreatitis (Balthazar score) 
 A: normal pancreas: 0 
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 B: enlargement of pancreas: 1 
 C: inflammatory changes in pancreas and peripancreatic fat: 2 
 D: ill-defined single peripancreatic fluid collection: 3 
 E: two or more poorly defined peripancreatic fluid collections: 4 
Pancreatic necrosis  
 none: 0 
 ≤30%: 2 
 >30-50%: 4 
 >50%: 6 
The maximum score that can be obtained is 10. 
Treatment and prognosis 
The CTSI is the sum of the scores obtained with the evaluation of pancreatic necrosis 
and the Balthazar score: 
 0-3: mild acute pancreatitis 
 4-6: moderate acute pancreatitis 
 7-10: severe acute pancreatitis 
 
ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY 
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ERCP has norole in diagnosing Acute Pancreatitis. When compared to traditional 
medical treatment alone, therapeutic application of ERCP in moderate-tosevereacute 
gallstone pancreatitis has been shown by several controlledclinical trials to lower 
mortality andmorbidity. ERCP is also utilizedin the differential diagnosis and elective 
treatment of recurrent unexplainedpancreatitis secondary to sphincter Oddi 
dysfunction, pancreaticdivisum, and microlithiasis [40-42]. 
 
ENDOSCOPIC ULTRASOUND 
 
 
The diagnostic role of EUS in Acute Pancreatitis is stillevolving; it is not easily 
available in all institutions. In recent studies,the immediate application of EUS for 
suspected biliary AP may aidin the diagnosis of gallstone pancreatitis, thereby helping 
to triage patients for therapeutic ERCP with endoscopic sphincterotomy andstone 
removal[43]. 
 
 
 
 
 
 
 
 
 
3.10. MANAGEMENT OF AP 
 
Treatment 
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The severity of AP covers a broad spectrum of illness, ranging from the mild and self-
limiting to the life-threatening necrotizingvariety. Hospitalization of the patient with 
suspected acute pancreatitis for observation and diagnostic study is usuallymandatory 
regardless of severity. Patients with moderate to severe disease should be transferred 
to the intensive care unit forobservation and maximal support, upon confirmation of 
the diagnosis. The initial treatment most importantlyis conservative intensive care 
with the goals of oral fluid and food restriction, replacement of electrolytes and fluids 
parenterally as assessed by urinary excretion,central venous pressure and control of 
pain. Most experts recommend broad-spectrum antibiotics insevere acute pancreatitis, 
or when signs of infection are present, (e.g., imipenem) and carefulsurveillance for 
complications of the disease[44](Fig 18). 
 
Mild pancreatitis 
Treatment of mild pancreatitis is supportive. Patients require hospital admission, 
where they should receive intravenouscrystalloid fluids and appropriate analgesia and 
should stop all oral intake. Most patients will require opiate analgesia,although this 
may cause the sphincter of Oddi spasm, there is no evidence that this affects the 
outcome of the disease. The severe pain of acute pancreatitis results in ongoing 
cholinergic discharge whichprevents the patient from resting and also stimulates 
pancreatic and gastric secretion. Therefore, management of pain is of great 
importance. Administration of meperidine,buprenorphine, procaine hydrochloride, and 
pentazocine are all of value in controlling abdominal pain. 
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A NG tube may be helpful if vomiting is severe. In the absence of coexisting 
infectionsantibiotics are of no benefit.Investigations are limited to the ultrasonography 
and initial blood tests when gall stones are suspected. Most patients will recover in 
48-72 hours, and fluids can be restarted once abdominal pain and tenderness are 
resolving[30]. 
A low-fat, low-protein diet is advocated as the initial form of nutrition following an 
attack of acute pancreatitis[44]. 
 
Severe pancreatitis 
For close monitoring of patients with severe pancreatitis, they should be admitted to 
anintensive care or high dependency unit.Adequate resuscitation of hypovolemic 
shock withlarge volumes of fluids over the first twenty-four - forty-eight hours 
remains the cornerstone of management. To restore circulating volume,resuscitation is 
mainly with crystalloids but colloids may be required.Progress is monitored by 
ensuring that urine output is adequate (> 30 ml/hr.). Measurement of pulmonary 
arterial or central venous pressure may be required, particularly in patients 
withcardiorespiratory compromise.  
 
Patients who develop renal failure and adult respiratory distress syndrome 
requiredialysis andventilation.The role of prophylactic antibiotics in severe 
pancreatitisremains unclear, but antibiotics with good penetration into pancreatic 
tissue (such as high dose cefuroxime and imipenem) have shown amarginal benefit 
inrecent randomised trials. Patients with severe gallstone pancreatitis and biliary 
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sepsisor obstruction benefit from ERCP and removal of stones from thecommon bile 
duct within the first 48 hours of admission. 
However, in patientswithout biliary obstruction,the benefit of sphincterotomy is 
equivocal. No effective drug has beendeveloped to prevent the development of severe 
pancreatitisdespite intensive search. 
Initial clinical trials of several new drugs including antagonists of PAF (Lexipafant) 
and free radical scavengers that may limitpropagation of the cytokine cascade have 
been disappointing buthold theoretical promise[30]. 
When deterioration occurs after the first week,the possibility of infection inthe 
necrotic process should be considered. Infection can usually beconfirmed by CT 
guided fine needleaspiration. Patients with infected pancreatic necrosis have a 
70%mortality and require surgical debridement (necrosectomy). In patients without 
infection,the role of necrosectomy is unclear.Several new approaches are being 
investigated, including the use ofenteral rather than parenteral nutrition, which may 
reduce gutpermeability and bacterial translocation and limit infection inthe necrotic 
pancreas and the use of minimally invasive necrosectomy and lavage. 
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Fig 18.Algorithm for managing acute pancreatitis 
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3.11. COMPLICATIONS OF AP 
 
 
Complications of Acute Pancreatitis[44] 
I. Local 
A. Pancreatic phlegmon 
B. Pancreatic abscess 
C. Pancreatic pseudocyst 
D. Pancreatic ascites 
E. Involvement of adjacent organs, withfistula formation, thrombosis, 
mechanicalObstruction, obstructive jaundice, haemorrhage, orbowel infarction. 
II. Systemic 
A. Pulmonary 
1. Pneumonia, atelectasis 
2. Acute respiratory distress syndrome 
3. Pleural effusion 
B. Cardiovascular 
1. Hypotension 
2. Hypovolemia 
3. Sudden death 
4. Nonspecific ST-T wave changes 
5. Pericardial effusion 
C. Hematologic 
1. Hemoconcentration 
2. Disseminated intravascular coagulopathy 
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D. GI haemorrhage 
1. Peptic ulcer 
2. Erosive gastritis 
3. Splenic vein or Portal vein thrombosis with varices. 
E. Renal 
1. Oliguria 
2. Azotaemia 
3. Renal artery/vein thrombosis 
F. Metabolic 
1. Hyperglycaemia 
2. Hypocalcaemia 
3. Hypertriglyceridemia 
4. Encephalopathy 
5. Sudden blindness (Purtscher's retinopathy) 
G. Central nervous system 
1. Psychosis 
2. Fat emboli 
3. Alcohol withdrawal syndrome 
H. Fat necrosis 
1. Intra-abdominal saponification 
2. Subcutaneous tissue necrosis 
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3.12. URINARY AMYLASE 
 
Amylase from  pancreatic acini goes through pancreatic duct  into the 
duodenum.(Fig 19) 
 
               
          Fig 19.Amylase metabolism. 
 
An amylase is a small unit and it can pass through the glomeruli and found in the 
urine.Urinary amylase clearance is increased in acute pancreatitis from normal to 3 
folds. A value of > 550 U/L has a sensitivity of 62 % and 97% specific for acute 
pancreatitis.In damage to pancreas or salivary glands more enzyme in blood and this is 
excreted in the urine. In pancreatitis there is prolonged raised level of amylase in urine 
may be raised till 5 to 7 days.Short lived peak in blood, may be 1 to 2 days and return 
to normal [45]. 
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In acute pancreatitis Amylase picture is: 
1. Initial rise 2 to 12 hours. 
2. Peak level is 12 to 72 hours. 
3. Normal level reaches in three to four days. 
4. Urine amylase may remain elevated up to 2 weeks after the acute 
episode of acute pancreatitis.(Fig 20) 
      
   Fig 20. 
 
The urinary amylase is a highly sensitive indicator of the presence of acute 
pancreatitis. The urinary excretion always remained abnormal when the serum 
concentration was abnormal, and the excretion remained abnormal for two to fifty 
days even after the serum concentration had returned to normal in the absence of renal 
insufficiency [7]. Thus the urinary amylase excretion can be used for the diagnosis of 
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subsiding pancreatitis and for convalescent care of acute pancreatitis, such as the 
discontinuation of bed rest, initiation of oral feeding and the start of exercise. 
 
Urinary clearance of pancreatic enzymes from the circulation increases during 
pancreatitisin many cases; henceforth, urinary levels may be more sensitive than 
serum levels. Hence, it is recommended that amylase concentrations also be measured 
in the urine. Urinary amylase levels remainselevated for severaldays after serum levels 
have returned to normal. In patients with severe pancreatitis associated with 
significant necrotic damage, the pancreas may not release large amounts of enzymes 
into the circulation[38]. 
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CHAPTER 4 : MATERIALS AND METHODS 
 
4.1. SOURCE OF DATA  
 4.2. TYPE OF STUDY 
 4.3. NUMBER OF GROUPS STUDIED 
 4.4. SAMPLE SIZE 
 4.5. INCLUSION CRITERIA 
 4.6. EXCLUSION CRITERIA 
 4.7. PARAMETERS STUDIED 
 4.8. PROCEDURE  
 4.9. METHOD OF STATISTICAL ANALYSIS 
 4.10. ETHICAL CONSIDERATIONS 
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4.1. SOURCE OF DATA 
All patients admitted in Thanjavur medical college Hospital, during 2016 
December to 2017September with clinically suspected acute pancreatitis in the 
age group 25-45 and with CT findings suggestive of acute pancreatitis will be 
analysed prospectively. Data on duration of symptoms, clinical findings, serum 
amylase, serum lipase, urinary amylase,complete hemogram, renal function 
test, presence of SIRS, BISAP Score and CTSI will be recorded within 24 
hours of admission. Their clinical significance, correlation with severity and 
sensitivity of urinary amylase for the diagnosis of acute pancreatitis will be 
statistically analysed. 
4.2. TYPE OF STUDY 
One year Prospective study  
4.3. NUMBER OF GROUPS STUDIED 
Patients admitted with clinically suspected acute pancreatitis in the age group 
25-45, with CT findings suggestive of acute pancreatitis in the department of 
general surgery. 
4.4. SAMPLE SIZE  
This study will be carried out on 50 patients admitted with a diagnosis of acute 
Pancreatitis. This study will be carried out from 2016 December to 
2017September. 
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4.5. INCLUSION CRITERIA 
1.All patients admitted with clinically suspected acute pancreatitis in the age 
group (25-45) both male and female. 
2.CT findings suggesting acute pancreatitis. 
4.6. EXCLUSION CRITERIA 
 Known diabetic, hypertensive and patients with chronic kidney disease. 
 Drop outs and patients not willing for study. 
4.7. PARAMETERS STUDIED 
Data on patient's duration of symptoms, clinical findings,serum amylase, serum 
lipase, urinary amylase,complete hemogram, renal function test, presence of 
SIRS, BISAP Score and CTSI will be recorded. Statistical analysis will be 
carried out. 
4.8. PROCEDURE  
The Questionnaire proforma is designed based on objective of the study. And it 
has been piloted already and suitably modified (Proforma enclosed).  
It contains the following details: 
 Name 
 Age and sex 
 Complaints 
 Duration of symptoms 
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 Pain radiating to back 
 Known alcoholic 
 Last alcohol intake 
 Smoker 
 Previous history 
 Comorbidities 
 Vitals(PR,Blood pressure) 
 Presence of jaundice, hydration, fever, abdominal tenderness, guarding. 
 Investigations (Complete hemogram, LFT, RFT, Serum amylase, Serum lipase, 
Urinary amylase, USG abdomen, CECT) 
 SIRS, BISAP score 
 CTSI 
 
All the above details were recorded. BISAP score and CTSI were calculated 
and severity of pancreatitis identified.Serum amylase and urinary amylase was 
done by Kit method with reagent used CNP-G3, and serum lipase by enzyme 
calorimetric method.The biological reference value for diagnosis of AP was 
taken as 28-100 U/L for serum amylase, >60 for serum lipase and >321 for 
urinary amylase. 
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4.9. METHOD OF STATISTICAL ANALYSIS 
 
Results were expressed as mean±SE. Statistical analyses were made using Pearson 
Chi square test and Pearson correlation. P value < 0.05 was accepted as statistically 
significant. The predictive value of Urinary amylase over serum amylase was 
calculated by Receiver - Operating Characteristics (ROC) curve. 
4.10. ETHICAL CONSIDERATIONS 
This is an observational study. Informed consent will be obtained. In this study 
patients will be undergoing treatment and follow up on a regular basis. 
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OBSERVATION 
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CHAPTER 5: OBSERVATION 
 
 
A total of fifty inpatients diagnosed with acute pancreatitis were studied. All in the 
age group 25-45 years. Out of the fifty cases 48 were male and 2 female. Among the 
50 cases 44 (88%) was alcohol related pancreatitis and 6 was gallstone induced 
pancreatitis(12%)(Fig 21.). Early presentation of the cases(less than 4 days)was 
observedin 32 patients (64%) and late presentation (more than 4 days) was seen in 18 
members(36%)(Fig 22.). 
 Systemic inflammatory response syndrome was evident in 38 patients (76%) and was 
not present in the rest 12 patients(24%)(Fig 23.). Bedside index in severity of 
Pancreatitis Score was 0-2 in 47 patients (94%) and 3-5 in 3 patients(6%)(Fig 24). 
Based on CTSeverity Index 38 cases (76%) had mild acute pancreatitis(0-3) and 12 
had moderate acute pancreatitis(4-6) (24%), none had severe acute pancreatitis (7-
10)(Fig 25.).  
Urinary amylase was elevated in all 50 cases(Table 6,6.1).Serum amylase was 
elevated >100U in 38 cases,but significant (three times the upper limit >300U) in only 
18 cases, and 12 cases had normal values(Fig 26,Table 4). Serum lipase was elevated 
(>60U) in 49 cases(98%) and normal in only 1 case(2%)(Fig 27, Table 5). Also 
urinary amylase was found to be grossly elevated (>1001 U) in 17(34%)patients(Fig 
28,29).Among these, 7 patients had a CTSI 0-2(mild AP) and 10 patients(83.3%) had 
a CTSI >3(Moderate AP).But those with urinary amylase in the range 321-1000 only 
2(16.7%) had CTSI>3-Moderate AP(Table 10,Fig 30). All the 18 cases with late 
presentation of AP had their serum amylase values either in the normal range (28-
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100U) or less than three times the upper limit (<300U), but urinary amylase was 
consistently elevated in all these cases.  
 
 
 
Fig 21.      Fig 22. 
 
 
 
 
Fig 23.      Fig 24. 
 
 
Fig 25. 
 
 
88%
12%
Etiology
Alcohol realted pancreatitis
Gallstone induced pancreatitis
64%
36%
Duration of 
symptoms
< 4days > 4days
76%
24%
SIRS
Present Absent
94%
6%
BISAP
0 to 2 3 to 5
76%
24%
0%
CTSI
0 to 3 4 to 6 7 to 10
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1.ANALYSIS OF SERUM AMYLASE LEVEL: 
 
 
Table 4.Serum amylase 
 
 
Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid 
Below 
100 
12 24.0 24.0 24.0 
100 to 
300 
20 40.0 40.0 64.0 
300 & 
above 
18 36.0 36.0 100.0 
Total 50 100.0 100.0  
 
 
 
 
 
 
 
 
Fig.26 
 
 
 
 
 
 
 
 
24%
40%
36%
Serum amylase
<100 100-300 300 and above
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2. ANALYSIS OF SERUM LIPASE LEVEL. 
 
 
 
Table 5.Serum lipase 
 
 
Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
Valid 
Below 
60 
1 2.0 2.0 2.0 
Above 
61 
49 98.0 98.0 100.0 
Total 50 100.0 100.0  
 
 
    
 
Fig 27. 
 
 
 
3. ANALYSIS OF URINARY AMYLASE LEVEL. 
 
 
 
Table 6. Urinary amylase 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid >320 50 100.0 100.0 100.0 
 
 
 
2%
98%
Serum Lipase
Below 60 Above 60
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Table 6.1 -Grossly elevated Urinary amylase levels 
 
 
Frequency Percent Valid Percent Cumulative Percent 
Valid 
321 to 1000 33 66.0 66.0 66.0 
> 1001 17 34.0 34.0 100.0 
Total 50 100.0 100.0  
 
 
 
 
 Fig 28. 
 
 
 Fig 29. 
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4.TABLE SHOWING DESCRIPTIVE STATISTICS. 
Table 7.Descriptive Statistics 
 
 
N Minimum Maximum Mean Std. Deviation 
Duration of symptoms 50 1 7 2.96 1.498 
Serum amylase 50 70 814 286.29 204.307 
Serum lipase 50 50 876 341.85 210.936 
Urinary amylase 50 417 1778 927.12 372.796 
BISAP score 50 0 3 1.24 .870 
CTSI score 50 1 5 2.36 1.290 
Valid N (list wise) 50     
 
5. TABLE SHOWING STATISTICAL COMPARISION OF SERUM AND 
URINARY AMYLASE AND ITS SIGNIFICANCE 
Table 8. Crosstab Serum and urinary amylase 
 
 
Urinary amylase 
Total 
321 to 
1000 
> 1001 
 
Serum 
amylase 
Below 100 
Count 10 2 12 
% within Urinary 
amylase 
30.3% 11.8% 24.0% 
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100 to 300 
Count 18 2 20 
% within Urinary 
amylase 
54.5% 11.8% 40.0% 
300 & 
above 
Count 5 13 18 
% within Urinary 
amylase 
15.2% 76.5% 36.0% 
Total 
Count 33 17 50 
% within Urinary 
amylase 
100.0% 100.0% 100.0% 
 
6. TABLE SHOWING T-Test OF URINARY AMYLASE AND ITS 
SIGNIFICANCE. 
Table 9.Chi-Square Tests 
 
 
Value df Asymp. Sig. (2-sided) p value 
Pearson Chi-Square 18.459(a) 2 .000 
Likelihood Ratio 19.016 2 .000 
Linear-by-Linear Association 11.974 1 .001 
N of Valid Cases 50   
P value <0.5 is significant 
 
 
P a g e  | 88 
 
7. TABLE SHOWING STATISTICAL CORRELATION OF URINARY       
AMYLASE WITH CTSI. 
Table 10. Crosstab correlation Of CTSI and Urinary amylase 
 
 
CTSI score 
Total 
1 to 3 
4 & above 
 
Urinary amylase 
321 to 1000 
Count 31 2 33 
% within CTSI score 81.6% 16.7% 66.0% 
> 1001 
Count 7 10 17 
% within CTSI score 18.4% 83.3% 34.0% 
Total 
Count 38 12 50 
% within CTSI score 100.0% 100.0% 100.0% 
 
 
Fig 30. 
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8.SENSITIVITYOF SERUM AMYLASE. 
ROC CURVE  
ROC Curve
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Fig 31. 
Table 11. Area Under the Curve  
Test Result Variable(s): Serum amylase 
Area 
Std. 
Error(a) 
Asymptotic 
Sig.(b) 
Asymptotic 95% Confidence 
Interval 
Lower 
Bound 
Upper Bound 
.171 .077 .000 2.031E-02 .322 
a Under the nonparametric assumption 
b Null hypothesis: true area = 0.5 
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Coordinates of the Curve  
Test Result Variable(s):Serum amylase 
Positive if morethan or Equal To(a) Sensitivity 
1 - 
Specificity 
68.90 1.000 1.000 
72.65 .970 1.000 
76.70 .970 .941 
81.50 .939 .941 
85.25 .939 .882 
86.65 .909 .882 
88.50 .879 .882 
91.40 .848 .882 
94.80 .818 .882 
96.50 .788 .882 
97.85 .758 .882 
99.35 .727 .882 
102.00 .697 .882 
108.15 .667 .882 
124.20 .636 .882 
141.20 .606 .882 
148.15 .576 .882 
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153.20 .545 .882 
156.50 .515 .882 
162.40 .485 .882 
175.15 .455 .882 
193.00 .455 .824 
204.80 .424 .824 
208.85 .394 .824 
215.75 .364 .824 
221.30 .333 .824 
224.90 .303 .824 
231.35 .273 .824 
240.50 .242 .824 
253.55 .212 .824 
276.25 .182 .824 
295.20 .182 .765 
315.70 .152 .765 
332.00 .121 .765 
333.85 .121 .706 
362.60 .091 .706 
394.35 .091 .647 
P a g e  | 92 
 
419.30 .091 .588 
445.10 .061 .588 
451.25 .061 .529 
455.20 .030 .529 
469.15 .000 .529 
510.10 .000 .471 
544.80 .000 .412 
555.25 .000 .353 
589.60 .000 .294 
643.45 .000 .235 
690.35 .000 .176 
750.85 .000 .118 
801.90 .000 .059 
815.20 .000 .000 
The smallest cutoff value is the minimum observed test value minus 1, and the largest 
cutoff value is the maximum observed test value plus one. All the other cutoff values 
are the averages of 2 consecutive ordered observed test values. 
 
Sensitivity is around 70% if diagnostic value is taken as >100. 
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9. SENSITIVITY OF URINE AMYLASE. 
ROC Curve
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                        Fig 32. 
 
 
 
Table 12. Area Under the Curve  
Test Result Variable(s): Urinary amylase 
Area 
Std. 
Error(a) 
Asymptotic 
Sig.(b) 
Asymptotic 95% Confidence 
Interval 
Lower Bound Upper Bound 
.239 .084 .007 7.346E-02 .405 
a Under the nonparametric assumption 
b Null hypothesis: true area = 0.5 
Coordinates of the Curve  
Test Result Variable(s): Urinary amylase 
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Positive if morethan or Equal To(a) Sensitivity 1 - Specificity 
415.80 1.000 1.000 
423.20 .917 1.000 
442.15 .833 1.000 
472.00 .833 .974 
494.40 .833 .947 
513.15 .833 .921 
527.35 .833 .895 
533.95 .833 .868 
547.05 .750 .868 
557.10 .667 .868 
562.10 .583 .868 
564.45 .500 .868 
566.00 .500 .842 
578.60 .417 .842 
601.20 .417 .816 
647.90 .333 .816 
683.70 .333 .789 
685.55 .333 .763 
698.20 .250 .763 
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732.85 .167 .763 
761.50 .167 .737 
776.10 .167 .711 
785.85 .167 .684 
789.35 .167 .658 
844.60 .167 .632 
910.10 .167 .605 
942.80 .167 .579 
963.50 .167 .553 
973.15 .167 .526 
989.90 .167 .500 
998.80 .167 .474 
999.45 .167 .447 
1000.30 .167 .421 
1001.55 .167 .395 
1018.90 .083 .395 
1087.20 .083 .368 
1164.10 .083 .342 
1195.10 .083 .316 
1211.50 .083 .289 
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1223.05 .083 .263 
1256.50 .083 .237 
1307.05 .083 .211 
1341.00 .083 .184 
1400.95 .083 .158 
1463.80 .083 .132 
1512.35 .083 .105 
1542.35 .083 .079 
1543.25 .000 .079 
1653.35 .000 .053 
1770.35 .000 .026 
1778.90 .000 .000 
The smallest cutoff value is the minimum observed test value minus one  and the largest 
cutoff value is the maximum observed test value plus 1. All the other cut off values are 
the average of 2 consecutive ordered observed test values. 
 
The Sensitivity for urinary amylase value >500 is around 83%. 
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CHAPTER 6 :  DISCUSSION 
Acute Pancreatitis is one of the commonest surgical emergencies. The diagnosis of 
acute Pancreatitis is primarily clinical. A typical patient presents with severe upper 
abdominal pain (epigastric) radiating to the back, nausea and vomiting and has got 
tenderness and sometimes guarding in the epigastric region on examination. There 
may be history of heavy alcohol consumption. The definite diagnosis of Pancreatitis 
still remains a clinical decision augmented by appropriate tests.  
Serum amylase is commonly used than any other test in assisting the diagnosis of 
acute pancreatitis. The diagnosis of pancreatitis is not a problem in patients with 
typical symptoms of acute pancreatitis or elevated serum amylase values. Diagnostic 
problems are encountered in the acute cases with atypical presentation or that have 
partially subsided or in the atypical cases with normal or subclinical serum amylase 
value. Newer investigations like serum procalcitonin, IL -6 and urinary trypsinogen-2 
are now used in the diagnosis of acute pancreatitis.But most of these investigations are 
expensive and require trained personnel. 
 
Reports from Saxon et al1, Budd et al2 , and Gambill et al3 has shown that the hourly 
excretion rate of urinary amylase could be more frequently abnormal in the presence 
of pancreatic diseases than the serum concentration of either amylase or lipase. In 
uncomplicated cases of AP Serum amylase usually remains elevated for 3–5 
days.Lower activities does not rule out the diagnosis, as serum amylase activity may 
reduce or becomes normal within the first 24-48 hours. Measurement of urinary 
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amylase activity, which remains high for longer periods, may be helpful in this 
situation5. 
 
Urinary amylase is increased in acute pancreatitis and may remain elevated for 7 to 10 
days after serum levels have returned to normal6.Thus it is useful in diagnosis of 
atypical cases with normal serum amylase and those cases with late presentation of 
AP.  
Urinary amylase may also be useful in cases of hypertriglyceridemia and 
macroamylasemia in which serum amylase values may be misguiding diagnosis of 
AP.There are not much studies conducted on the clinical significance of urinary 
amylase inAP.  
 
Thus this study was conducted to assess theclinical significance and sensitivity of 
urinary amylase in the diagnosis of acute pancreatitis, and its correlation to severity 
was analysed. 
 
In this Study of 50 cases of acute pancreatitis, it was found that urinary amylase 
was significantly elevated in all cases with Acute Pancreatitis. In cases with early 
presentation duration less than 4 days, both serum and urinary amylase were 
equally elevated. In those with late presentation, though serum amylase was not 
significantly elevated or normal in some atypical cases, urinary amylase was 
grossly elevated in those cases. In cases with moderate acute pancreatitis urinary 
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amylase levels were more elevated than those with mild AP, thus correlating with 
the severity of AP. 
 
One study was conducted in1970 by TETSUO HAYAKAWA et al to find the clinical 
significance of urinary amylase in diagnosis of pancreatic diseases. This study has 
concluded that the urinary amylase is a highly sensitive indicator of the presence of 
acute pancreatitis. The urinary excretion of amylase remained always abnormal 
whenever the serum concentration was abnormal and the excretion remained abnormal 
for two to 50 days even after the serum concentration had returned to normal in the 
absence of renal insufficiency7. Thus the urinary amylase excretion can be used for the 
diagnosis of subsiding pancreatitis and for convalescent care of acute pancreatitis, 
such as the discontinuation of bed rest, initiation of oral feeding and the start of 
exercise. 
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CHAPTER 7 : RESULTS 
Among 50 patients, 38 had mild AP and 12had moderateAP, none had SAP based on 
CTSI. Serum amylase, Serum lipase and Urinary amylase were analysed on the first 
day of admission within 24 hours.Males are more commonly affected than females. 
Alcohol was the leading cause of AP followed by Gall stones. In this study the 
biological reference value was taken as per lab, for serum amylase (28-100U/L), 
Serum lipase (>60 U/L) and urinary amylase (>321 U/L). The percentageof patients 
for mild and moderate AP for significant rise in serum amylase (3 times the upper 
limit), Serum lipase and urinary amylase includes 36%, 98% and 100% respectively. 
The standard deviation of serum amylase, serum lipase and urinary amylase includes 
204.307,210.936 and 372.796 respectively.The statistical inference of all the three 
parameters comparing one value with other parameters shows serum andurinary 
amylase has significant value of P<0.05. Urinary amylase was found to be grossly 
elevated (>1000 U) in 17 patients. Among these, 3 patients had a BISAP Score >2 and 
10 patients had moderate acute pancreatitis, thus correlating with disease severity. All 
the 18 cases with late presentation of AP had their serum amylase values either in the 
normal range (28-100U) or less than three times the upper limit (<300U), but urinary 
amylase was consistently elevated in all these cases.The values of urinary amylase 
was found to be more sensitive than serum amylase in diagnosis acute pancreatitis. 
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CHAPTER 8 : CONCLUSION 
1.Urinary amylase is more sensitive than serum amylase in diagnosis of acute 
pancreatitis. 
 
2.It is especially useful in cases of acute pancreatitis with late presentation, or atypical 
cases with normal serum amylase values. 
 
3.It can also be useful in cases of macroamylasemia and hypertriglyceridemia were 
serum amylase values are not relevant. 
 
4. It also correlates with the severity of pancreatitis.Urinary amylase is grossly 
elevated in patients with Moderate acute pancreatitis  than mild acute pancreatitis in 
this study.  
 
 
5.Thus Urinary amylase estimation can be a very useful non-invasive diagnostic tool 
for diagnosing atypical cases of AP thus reducing the morbidity in cases of AP which 
are missed are misdiagnosed with normal or insignificant rise in serum amylase value. 
. 
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10.1. CONSENT FORM 
 
I __________________________________________  hereby give consent to 
participate in the study conducted by DR.SUGUMARAN.K,  post graduate in 
department of GENERAL SURGERY ,Thanjavur medical college & 
hospital,Thanjavur – 613004 and to use my personal clinical data and result of 
investigation for the purpose of analysis and to study the nature of disease. I also give 
consent for further investigations. 
 
 
 
 
 
 
 
Place : 
Date :       Signature of participant 
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10.2. PROFORMA 
DISSERTATION ON CLINICAL SIGNIFICANCE OF SERUM AND URINARY 
AMYLASE IN ACUTE PANCREATITIS 
DEPARTMENT OF GENERAL SURGERY 
THANJAVUR MEDICAL COLLEGE 
Name:     Age/sex:   IP NO:   
         DOA: 
Complaints: 
Duration of symptoms: 
Pain radiating to back: 
Known alcholic :    Last alcohol intake: 
Smoker: 
Previous history: 
Comorbidities: 
Clinical examination:  
General condition:     Vitals: PR:    BP: 
Jaundice:  Hydration:    Fever: 
Abdomen: Distension:   
Epigastric tenderness:      Guarding/rigidity: 
Others: 
 
Investigations: 
Hb:              TC:                DC:    Platelet: 
LFT: 
RFT:  SIRS:    BISAP SCORE: 
Serum amylase:   Urinary amylase:  (clean catch/catheter 
sample)  
Serum lipase:   Serum calcium: 
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USG ABDOMEN: 
 
CT ABDOMEN: 
 
CT SEVERITY INDEX: 
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10.3. DATA SHEET 
S.NO Name Duration 
of 
symptoms 
Serum 
amylase 
Serum 
lipase 
Urinary 
amylase 
SIRS BISAP CTSI 
1 Durai manikam 1 day 618.3 445.6 1777.9 + 3 5 
2 Jayabal 2 days 245 330 564.8 + 2 2 
3 Kanan 3 days 549.6 545.3 1200.9 + 2 4 
4 Karrupayi 4 days 236.0 109.7 999.8 + 1 2 
5 Mahalingam 2 day 814.2 376.6 1762.8 + 3 5 
6 Manikam 4 days 96 120 554.1 + 1 2 
7 Pichairaj 3 days 290.4 142.3 1035.5 + 2 4 
8 Raju 5 days 93.6 49.9 416.8 + 1 2 
9 Rajendiran 3 days 85.5 67.4 429.6 + 1 1 
10 Rajkumar 4 days 262.1 835.0 923.6 + 1 2 
11 Sambath 3 days 156.6 242.6 526.8 + 1 1 
12 Shankar 1 day 390.1 702.1 1289 + 2 2 
13 Sivanantham 4 days 98.7 218.0 612.4 - 0 1 
14 Suresh 2 days 203.9 325.7 527.9 - 0 1 
15 Thangavel 5 days 219.5 162.9 766.6 - 0 1 
16 Thirunavukarasu 5 days 75.4 76.2 1542.6 + 2 2 
17 Tilak 1 day 450.2 611 1542.1 + 3 5 
18 Arun 2 days 398.6 540 1325.1 + 2 4 
19 Kabilan 1 day 540 446.2 1482.6 + 2 5 
20 Duraisamy 5 days 89.2 220 560.1 - 0 2 
21 Dhanabal 3 days 104 352 683.4 + 1 1 
22 Chandrasekar 1 day 331.4 254 792.6 + 2 2 
23 Patamal 3 day 223.1 356.6 999.1 + 1 2 
24 Charu 2 days 440 650.1 1000.8 + 2 5 
25 Murugesh 4 days 112.3 332.8 785.6 + 1 2 
26 Mani 1 day 335.1 452.8 998.5 + 2 4 
27 Dhayalan 5 days 87.8 204.1 709.3 - 0 2 
28 Vigneshwaran 1 day 712.1 560.3 1189.3 + 2 2 
29 Kumerasan 2 days 452.3 515 896.6 + 1 2 
30 Sivakumar 4 days 78 66.4 687.1 - 0 2 
31 Arul 3 days 226.7 365.2 981.3 + 1 2 
32 Gopinath 5 days 85 90.6 1002.3 + 1 2 
33 Vivek 1 day 560.9 486.1 1543.9 + 2 5 
34 Anand 1 day 332.6 432 1222.1 + 1 2 
35 Balaguru 3 days 69.9 87 564.1 - 0 1 
36 Ramki 4 days 168.2 156.8 499.5 - 0 2 
37 Palanivel 2 days 458.1 501.2 786.1 + 1 2 
38 Guna 5 days 97 60.2 567.2 - 0 2 
39 Anbumani 1 day 668.6 450.9 1138.9 + 2 5 
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40 Ashok 3 days 156.4 100.6 489.3 - 0 1 
41 Senthil 2 days 300 258.4 756.4 + 1 2 
42 Kaushik 1 day 789.6 300.4 1356.9 + 2 4 
43 Santhosh 3 days 146.3 366 962 - 1 2 
44 Kameraselvam 4days 182.1 751.9 1445.0 + 2 3 
45 Prabakaran 7 days 205.7 127.4 965 + 2 2 
46 Chinnathambi 2days 480.2 876.4 1224 + 2 3 
47 Boominathan 4days 150 418 590 + 1 1 
48 Anbu 3 days 100 412 540 + 1 1 
49 Ashok 5days 212 264 684 + 1 2 
50 Balasubramani 3days 136.1 276.9 454.7 - 0 1 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
